http://www.polity.org.za
Deepening Democracy through Access to Information
Home / News / All News RSS ← Back
Africa|AIDS Relief|ARVs|Clinton Health Access Initiative|Health|Resources|Africa|Kenya|South Africa|United States|HIV Treatment|AIDS|HIV|HIV Epidemic Control|Malaria|Antiretroviral Therapy|Aaron Motsoaledi
Africa|Health|Resources|Africa|Kenya|||||
africa-company|aids-relief-company|arvs|clinton-health-access-initiative|health|resources|africa|kenya|south-africa|united-states|hiv-treatment|aids|hiv|hiv-epidemic-control|malaria|antiretroviral-therapy|aaron-motsoaledi
Close

Email this article

separate emails by commas, maximum limit of 4 addresses

Verification Image. Please refresh the page if you cannot see this image.

Sponsored by

Close

Article Enquiry

Lower ARV price to benefit S Africa, increase recipient numbers

Verification Image. Please refresh the page if you cannot see this image.
Close

Embed Video

Lower ARV price to benefit S Africa, increase recipient numbers

Photo by Reuters

22nd September 2017

By: Sashnee Moodley
Deputy Editor Polity and Multimedia

SAVE THIS ARTICLE      EMAIL THIS ARTICLE

Font size: -+

A new antiretroviral (ARV) pricing agreement reached by the South African government, international organisations and agencies will ensure that more people will have access to treatment, while saving South Africa nearly R12-billion over the next six years.

A statement released by the Department of Health on Friday revealed that the single-pill HIV treatment regimen containing dolutegravir (DTG) will be available to low and middle-income countries at a price of $75 per person, a year.

Advertisement

Minister of Health Aaron Motsoaledi said that the large volumes of ARVs purchased by South Africa were used to leverage the decrease in pricing.

“The agreement is expected to accelerate treatment roll-out as part of global efforts to reach all 36.7-million people living with HIV with high-quality antiretroviral therapy. South Africa will introduce the new fixed dose combination of three drugs, Tenofovir, Lamivudine and TLD in April 2018,” said Motsoaledi.

Advertisement

Dolutegravir is an extremely effective antiretroviral with fewer side effects. Patients are, therefore, more likely to be adherent and more likely to be virally suppressed – which means that they are not likely to transmit the virus to others.

Parties involved in the pricing agreement included South Africa together with Kenya, in partnership with the Clinton Health Access Initiative, the Joint United Nations Programme on HIV/Aids, the Bill & Melinda Gates Foundation, UNITAID, the UK’s Department for International Development, the US President’s Emergency Plan for AIDS Relief, the US Agency for International Development, and the Global Fund to Fight AIDS, Tuberculosis and Malaria.

“The considerable price reductions could yield savings of up to R11.7-billion over the next six years for us, which means that we can initiate additional patients on treatment with the same amount of resources. Ramping up treatment with good viral suppression will enable us to reach HIV epidemic control more quickly,” said Motsoaledi.

EMAIL THIS ARTICLE      SAVE THIS ARTICLE ARTICLE ENQUIRY

To subscribe email subscriptions@creamermedia.co.za or click here
To advertise email advertising@creamermedia.co.za or click here

Comment Guidelines

About

Polity.org.za is a product of Creamer Media.
www.creamermedia.co.za

Other Creamer Media Products include:
Engineering News
Mining Weekly
Research Channel Africa

Read more

Subscriptions

We offer a variety of subscriptions to our Magazine, Website, PDF Reports and our photo library.

Subscriptions are available via the Creamer Media Store.

View store

Advertise

Advertising on Polity.org.za is an effective way to build and consolidate a company's profile among clients and prospective clients. Email advertising@creamermedia.co.za

View options
Free daily email newsletter Register Now
Register Close